RLMD Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. (RLMD) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: September 10, 2026 , by TRAVERSA SERGIO .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| TRAVERSA SERGIO | Chief Executive Officer | Buy | 100,000 | $4.10 | $410.0K | 1,500,000 | |
| Shenouda Maged | Chief Financial Officer | Buy | 79,800 | $4.25 | $339.2K | 1,000,000 | |
| Shenouda Maged | Chief Financial Officer | Buy | 120,200 | $4.20 | $504.8K | 920,200 | |
| TRAVERSA SERGIO | Chief Executive Officer | Buy | 100,000 | $4.18 | $418.0K | 1,400,000 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.